Opinion

Video

Exploring the TROPION-Lung04 Study

Author(s):

Mark A. Socinski, MDHelena A. Yu, MD

Benjamin Levy, MD, presents an overview of the TROPION-Lung04 study in the first-line setting, focusing on the toxicity profile and potential impact on clinical practice.

  1. Please review the TROPION-Lung04 study in 1L setting. (Papadoupoulos et al. WCLC 2023)
    1. Briefly outline the study design and key endpoints and discuss the rationale for this treatment approach.
    2. What implications may these findings have on clinical practice
    3. Moderator followed up on ADC toxicities
Related Videos
Video 4 - 2 KOLs are featured in, "Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC"
Video 2 - 2 KOLs are featured in, "Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway"
4 KOLs are featured in this series
4 KOLs are featured in this series
Salman R. Punekar, MD
4 KOLs are featured in this series
4 KOLs are featured in this series
2 KOLs are featured in this series
2 KOLs are featured in this series
5 KOLs are featured in this peer exchange
Related Content
OncLive On Air® 
July 1st 2024

Revisit Every OncLive On Air Episode From June 2024

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Dave Fredrickson, executive vice president of the Oncology Business Unit, AstraZeneca
June 26th 2024

China’s NMPA Approves First-Line Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Susan Galbraith
June 25th 2024

Adjuvant Durvalumab Misses DFS End Point in Resected, PD-L1+ Stage IB-IIIA NSCLC

Jorge J. Nieva, MD, of Keck Medicine of University of Southern California
June 25th 2024

Addressing the Logistics of At-Home Cancer Care With Subcutaneous Administration of Immunotherapy